Market Overview:
The global guanfacine extended-release pill market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of ADHD and rising demand for better treatment options. Based on type, the global guanfacine extended-release pill market is segmented into 1mg/pill and 2mg/pill segments. The 1mg/pill segment is expected to account for a larger share of the global market in 2018, owing to its lower dosage as compared to 2mg/pill. However, the 2mg/pill segment is projected to grow at a higher CAGR during the forecast period, owing to its higher efficacy in treating ADHD symptoms as compared to 1 mg/pills. Based on application, the global guanfacine extended-release pill market is divided into two segments: Inattention in children and Children's emotional impulse control disorder (CEC). The Inattention in children segment accounted for a larger share of the global market in 2017 and is projected grow at a higher CAGR during 2018–2030 due high prevalence rate of ADHD across all regions globally .
Product Definition:
Guanfacine Extended-Release Pill is a medication used to treat high blood pressure and ADHD. It is important because it can help to lower blood pressure and improve focus in people with ADHD.
1mg/Pill:
1mg/Pill is a generic name for guanfacine, which is an anti-epileptic drug. It's main function is to prevent seizures in people suffering from epilepsy. Epilepsy is a chronic and incurable disease of the brain, causing repeated and prolonged seizures. According to the WHO statistics (2012), approximately 50 million people are living with epilepsy worldwide; out of which half are treated successfully with antiseizure drugs like 1mg/Pill.
2mg/Pill:
The 2mg/Pill is used for treating shortness of breath and it's also used in the treatment of sudden cardiac arrest. The drug has been approved by the U.S.
Application Insights:
Inattention in children was the largest application segment for guanfacine extended-release pills, accounting for over 60% of total demand in 2017. Guanfacine is a popular medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) and other conditions related to impulse control such as hyperactivity and excessive energy. Guanfacine is also used off label to treat anxiety associated with social situations among adolescents suffering from ADHD. The growing usage of guanfacine tablets for treating attention deficit hyperactivity disorder coupled with its non-addictive property has led to an increased market penetration across the globe.
The second largest application includes children¢â‚¬â„¢s emotional impulse disorder which accounted for over 20% of total demand in 2017 owing to high product efficacy observed during clinical trials against depression, anxiety disorders and other related conditions such as Oppositional defiant disorder (ODD).
Regional Analysis:
Asia Pacific dominated the global guanfacine extended-release pill market in 2017. The presence of a large number of manufacturers and suppliers coupled with increasing awareness about ADHD treatment options are some factors driving the growth. In addition, growing disposable income levels and improving healthcare infrastructure are expected to contribute to market growth over the forecast period.
The Asia Pacific region is also anticipated to witness significant growth during the forecast period owing to rising cases of attention-related disorders in children as well as adults due to stress, sleep deprivation, change in routine etc., which can be treated effectively by guanfacine ER tablets. Moreover, increasing awareness about mental health issues among people is contributing towards product demand from countries such as China & India where mental health care facilities are limited or non-existent thus making it an attractive option for patients seeking effective treatment for attention deficit/hyperactivity disorder (ADHD).
Growth Factors:
- Increasing prevalence of ADHD
- Growing awareness about the benefits of Guanfacine Extended-Release Pill over traditional therapies
- Rising demand for better treatment options for ADHD patients
- Availability of generic versions of Guanfacine Extended-Release Pill
- Technological advancements in the field of drug delivery
Scope Of The Report
Report Attributes
Report Details
Report Title
Guanfacine Extended-Release Pill Market Research Report
By Type
1mg/Pill, 2mg/Pill
By Application
Inattention in Children, Children's Emotional Impulse
By Companies
TWi Pharmaceuticals USA, Inc., Shire Pharmaceuticals, APOTEX, TEVA Generics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Guanfacine Extended-Release Pill Market Report Segments:
The global Guanfacine Extended-Release Pill market is segmented on the basis of:
Types
1mg/Pill, 2mg/Pill
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Inattention in Children, Children's Emotional Impulse
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- TWi Pharmaceuticals USA, Inc.
- Shire Pharmaceuticals
- APOTEX
- TEVA Generics
Highlights of The Guanfacine Extended-Release Pill Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 1mg/Pill
- 2mg/Pill
- By Application:
- Inattention in Children
- Children's Emotional Impulse
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Guanfacine Extended-Release Pill Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Guanfacine extended-release pill is a medication used to treat attention deficit hyperactivity disorder (ADHD). It is a tablet that you take once daily. Guanfacine extended-release pill helps to improve your ability to focus and concentrate, and reduces the symptoms of ADHD.
Some of the major players in the guanfacine extended-release pill market are TWi Pharmaceuticals USA, Inc., Shire Pharmaceuticals, APOTEX, TEVA Generics.
The guanfacine extended-release pill market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Guanfacine Extended-Release Pill Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Guanfacine Extended-Release Pill Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Guanfacine Extended-Release Pill Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Guanfacine Extended-Release Pill Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Guanfacine Extended-Release Pill Market Size & Forecast, 2020-2028
4.5.1 Guanfacine Extended-Release Pill Market Size and Y-o-Y Growth
4.5.2 Guanfacine Extended-Release Pill Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 1mg/Pill
5.2.2 2mg/Pill
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Inattention in Children
6.2.2 Children's Emotional Impulse
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Guanfacine Extended-Release Pill Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Guanfacine Extended-Release Pill Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 1mg/Pill
9.6.2 2mg/Pill
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Inattention in Children
9.10.2 Children's Emotional Impulse
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 1mg/Pill
10.6.2 2mg/Pill
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Inattention in Children
10.10.2 Children's Emotional Impulse
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 1mg/Pill
11.6.2 2mg/Pill
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Inattention in Children
11.10.2 Children's Emotional Impulse
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 1mg/Pill
12.6.2 2mg/Pill
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Inattention in Children
12.10.2 Children's Emotional Impulse
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 1mg/Pill
13.6.2 2mg/Pill
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Inattention in Children
13.10.2 Children's Emotional Impulse
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Guanfacine Extended-Release Pill Market: Competitive Dashboard
14.2 Global Guanfacine Extended-Release Pill Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 TWi Pharmaceuticals USA, Inc.
14.3.2 Shire Pharmaceuticals
14.3.3 APOTEX
14.3.4 TEVA Generics
